Table 2.

Multivariate analysis of outcomes for patients with malignant disease

EffectTransplant-related mortalityRelapseTreatment failure (1-DFS)Overall mortality
RR (95% CI)PRR (95% CI)PRR (95% CI)PRR (95% CI)P
Conditioning regimen  .46  .15  .12  .008 
 BuCy     
 BuFlu 1.2 (0.8-1.9)  1.2 (0.9-1.6)  1.2 (1-1.5)  1.4 (1.1-1.8)  
Age, y  <.001  .0002     
 0-9       
 10-18 2.5 (1.6-3.9)  0.6 (0.5-0.8)      
Sex  .044       
 Male        
 Female 0.7 (0.4-1)        
Donor type  .0002    .019  .006 
 HLA-identical sibling      
 8/8 unrelated 1.85 (1.2-2.8)    1.2 (1-1.5)  1.3 (1-1.6)  
 7/8 unrelated 2.74 (1.7-4.5)    1.5 (1.1-2)  1.6 (1.2-2.2)  
Disease status    <.001  <.001  <.001 
 Early      
 Intermediate   1.3 (1-1.8)  1.2 (0.9-1.6)  1.3 (1-1.7)  
 Advanced   2.5 (1.9-3.4)  2.1 (1.6-2.7)  2.3 (1.7-3)  
 Unknown   0.9 (0.6-1.4)  1 (0.7-1.3)  0.9 (0.6-1.2)  
EffectTransplant-related mortalityRelapseTreatment failure (1-DFS)Overall mortality
RR (95% CI)PRR (95% CI)PRR (95% CI)PRR (95% CI)P
Conditioning regimen  .46  .15  .12  .008 
 BuCy     
 BuFlu 1.2 (0.8-1.9)  1.2 (0.9-1.6)  1.2 (1-1.5)  1.4 (1.1-1.8)  
Age, y  <.001  .0002     
 0-9       
 10-18 2.5 (1.6-3.9)  0.6 (0.5-0.8)      
Sex  .044       
 Male        
 Female 0.7 (0.4-1)        
Donor type  .0002    .019  .006 
 HLA-identical sibling      
 8/8 unrelated 1.85 (1.2-2.8)    1.2 (1-1.5)  1.3 (1-1.6)  
 7/8 unrelated 2.74 (1.7-4.5)    1.5 (1.1-2)  1.6 (1.2-2.2)  
Disease status    <.001  <.001  <.001 
 Early      
 Intermediate   1.3 (1-1.8)  1.2 (0.9-1.6)  1.3 (1-1.7)  
 Advanced   2.5 (1.9-3.4)  2.1 (1.6-2.7)  2.3 (1.7-3)  
 Unknown   0.9 (0.6-1.4)  1 (0.7-1.3)  0.9 (0.6-1.2)  

CI, confidence interval.

Close Modal

or Create an Account

Close Modal
Close Modal